FLIR Systems Announces Artificial Intelligence Traffic Cameras for Predictive Traffic Management
9.11.2020 16:00:00 EET | Business Wire | Press release
FLIR Systems, Inc. today announced two intelligent traffic system cameras, the FLIR ThermiCam™ AI* with thermal imaging and the FLIR TrafiCam™ AI visible camera, both with artificial intelligence (AI) to optimize traffic flow on roadways and at intersections. When combined with the FLIR Acyclica™ cloud platform, cities can apply the AI-camera data to predict traffic, prevent congestion and potential accidents, and create safer roads for drivers, cyclists, and pedestrians 24 hours a day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005113/en/
Traffic engineers apply data from AI-enabled cameras, FLIR ThermiCam AI and TrafiCam AI, to predict traffic and prevent congestion and potential accidents for safer roads. (Photo: Business Wire)
“FLIR traffic systems are currently installed in 75 countries, and with the addition of ThermiCam AI and TrafiCam AI, FLIR now offers a fully integrated solution that enables traffic engineers and city planners to apply AI-based learnings to continuously optimize traffic flow,” said Rickard Lindvall, General Manager, Solutions Business, FLIR Systems. “The integrated solution enables cities to improve urban roadway design to make cities safer and more livable.”
The AI-enabled cameras help control traffic dynamically at the edge through real-time data capture and processing, and provide input to traffic signal controllers at intersections, which improves traffic flow and safety in the moment. With the ability to capture heat energy data through a thermal sensor within the ThermiCam AI, and a visible low-light, high-definition sensor within the TrafiCam AI, cities’ traffic signals have complete continuous monitoring, in all weather conditions and even through smoke for tunnel monitoring. The cameras are also Wi-Fi enabled for travel time calculations and other origin-destination applications. In the future, the cameras can be retrofitted with 5G cellular antennas to support vehicle-to-everything (V2X) connectivity, which will further improve road safety.
The FLIR Acyclica cloud platform provides the tools and analytics needed to better understand traffic data. When ThermiCam AI and TrafiCam AI are paired with the Acyclica cloud platform, cities can apply their AI-based learnings to real time data to make predictive traffic pattern changes for more efficient and safer cities.
The new AI traffic cameras are available globally in the first quarter of 2021. To learn more about FLIR ThermiCam AI and TrafiCam AI, visit www.flir.com/thermicam-ai and www.flir.com/traficam-ai. For more information about FLIR traffic solutions, visit www.flir.com/traffic/.
*The ThermiCam AI camera is sold as the TrafiSense ™ AI camera in the United States and Canada. To learn more visit www.flir.com/trafisense-ai.
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense, creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005113/en/
Contact information
Media Relations:
Eleana Stayer
Phone: +44 7545 204375
Email: eleana.stayer@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom